Table 1.
Baseline characteristics
| Sweden (n = 308) | UK (n = 183) | |
|---|---|---|
| Gender | ||
| Female | 266 (86.36%) | 150 (81.97%) |
| Male | 41 (13.31%) | 33 (18.03%) |
| Other/rather not say | 1 (0.32%) | 0 (0.00%) |
| Age | ||
| Mean (standard deviation) | 44.41 (11.72) | 43.83 (9.48) |
| ≤ 45 | 158 (51.30%) | 92 (50.27%) |
| > 45 | 150 (48.70%) | 91 (49.73%) |
| Cancer diagnosis | ||
| Breast | 110 (35.71%) | 82 (44.81%) |
| Cervical | 16 (5.19%) | 12 (6.56%) |
| Lung | 12 (3.90%) | 9 (4.92%) |
| Other | 161 (52.27%) | 77 (42.08%) |
| Missing data | 9 (2.92%) | 3 (1.64%) |
| COVID-19 pandemic wave | ||
| First | 125 (40.58%) | 154 (84.15%) |
| Second | 183 (59.42%) | 29 (15.85%) |
| COVID-19 test | ||
| Positive test | 22 (7.14%) | 8 (4.37%) |
| Negative test | 164 (53.25%) | 113 (61.75%) |
| No test | 117 (37.99%) | 61 (33.33%) |
| Missing data | 5 (1.62%) | 1 (0.55%) |
| Treatment | ||
| Undergoing treatment* | 141 (45.78%) | 97 (53.01%) |
| Not undergoing treatment | 159 (51.62%) | 80 (43.72%) |
| Missing data | 8 (2.60%) | 6 (3.28%) |
| Employment status | ||
| Employed | 230 (74.68%) | 113 (61.75%) |
| Not employed | 67 (21.75%) | 63 (34.43%) |
| Missing data | 11 (3.57%) | 7 (3.83%) |
*Of the 141 participants undergoing treatment in Sweden, 21 (14.89%) reported doing so exclusively at the hospital, 93 (65.96%) exclusively at home, and 27 (19.15%) at both. Of the 97 participants undergoing treatment in the UK, 16 (16.49%) reported doing so exclusively at the hospital, 52 (53.61%) exclusively at home, and 29 (29.90%) at both